A survey of Canadian gastroenterologists about the management of Barrett's esophagus

Canadian Journal of Gastroenterology

Volumn 17, Issue 5, 2003, Pages 313-317

  MacNeil Covin, Lisa ^a   Casson, Alan G ^a   Malatjalian, Dickran ^a   van Zanten, Sander Veldhuyzen ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Barrett's esophagus; Canada; Dysplasia; Gastroesophageal reflux disease; Screening; Survey

Indexed keywords

PROTON PUMP INHIBITOR;

ADULT; ARTICLE; BARRETT ESOPHAGUS; BIOPSY; CANADA; CHRONIC DISEASE; CLINICAL PRACTICE; CLINICAL PROTOCOL; CONTROLLED STUDY; DIGESTIVE TRACT ENDOSCOPY; DYSPLASIA; ESOPHAGUS CANCER; FREQUENCY ANALYSIS; GASTROENTEROLOGY; HEALTH SURVEY; HUMAN; LOW LEVEL LASER THERAPY; MEDICAL SPECIALIST; PHOTODYNAMIC THERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; SCREENING; STOMACH SURGERY;

EID: 0037772421     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2003/648497     Document Type: Article

References (38)

1. Eisen GM, Sandler RS, Murray S, Gottfried M. The relationship between gastroesophageal reflux disease and its complications with Barrett's esophagus. Am J Gastroenterol 1997;92:27-31.
2. Lagergren J, Bergstrom R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
3. Cameron AJ, Zinsmeiser AR, Ballard DJ, Carney JA. Prevalence of columnar-lined (Barrett's) esophagus. Gastroenterology 1990;99:918-22.
4. Splechler ST. Barrett's esophagus. N Engl J Med 2002;346:836-42.
5. Hameeteman W, Tytgat GNJ, Houthoff HJ, van den Tweel JG. Barrett's esophagus: Development of dysplasia and adenocarcinoma. Gastroenterology 1989;96:1249-56.
6. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: A prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997;92:212-5.
7. Miros M, Kerlin P, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's esophagus. Gut 1991;32:1441-6.
8. Ferraris R, Bonelli L, Conio M, et al. Incidence of Barrett's adenocarcinoma in an Italian population: An endoscopic surveillance programme. Eur J Gastroenterol Hepatol 1997;9:881-5
9. Achkar E, Carey W. The cost of surveillance for adenocarcinoma complicating Barrett's esophagus. Am J Gastroenterol 1988;83:291-4.
10. Shaheen NJ, Crosby MA, Boyzmski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000;119:333-8.
11. Byter P, Christensen PB, Damkier P, Vinding K, Seersholm N. Adenocarcinoma of the esophagus and Barrett's esophagus: A population-based study. Am J Gastroenterol 1999;94:86-91.
12. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287-94.
13. Farrow DC, Vaughan TL. Determinants of survival following the diagnosis of esophageal adenocarcinoma (United States). Cancer Causes Control 1996;7:322-7.
14. Steup WH, De Leyn P, Deneffe G, Van Raemdonck D, Coosemans W, Lerut T. Tumors of the esophagogastric junction. Long-term survival in relation to patterns of lymph node metastasis and a critical appraisal of the accuracy or inaccuracy of pTNM classification. J Thorac Cardiovasc Surg 1996;111:85-95.
15. Ellis FH, Heatley GJ, Krasna MJ, Williamson WA, Balogh K. Esophagogastrectomy for carcinoma of the esophagus and cardia: A comparison of findings and results after standard resection in three consecutive eight-year intervals with improved staging criteria. J Thorac Cardiovasc Surg 1997;113:836-48.
16. Casson AG, Tammemagi M, Eskandarian S, et al. p53 alterations in esophageal cancer: Association with clinicopathologic features and survival. Mol Pathol 1998;51:71-9.
17. Streitz JM, Andrews CW, Ellis FH. Endoscopic surveillance of Barrett's esophagus. Does it help? J Thorac Cardiovasc Surg 1993;105:383-8.
18. Sampliner RE, The Practice Patterns Committee of the American College of Gastroenterology. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 1998;93:1028-32.
19. Beck IT, Champion MC, Lemire S, et al. The second Canadian consensus conference on the management of patients with gastroesophageal reflux disease. Can J Gastroenterol 1997;11(Suppl B):7B-20B.
20. Boyer J, Robaszkiewiez M. Guidelines of the French Society of Digestive Endoscopy: Monitoring of Barrett's esophagus. The Council of the French Society of Digestive Endoscopy. Endoscopy 2000;32:498-9.
21. Provenzale D, Kemp JA, Arora S, Wong JB. A guide for surveillance of patients with Barrett's esophagus. Am J Gastroenterol 1994;89:670-80.
22. Falk GW, Ours TM, Richter JE. Practice patterns for the surveillance of Barrett's esophagus in the United States. Gastrointest Endosc 2000;52:197-203.
23. Gross CP, Canto MI, Hixson J, Powe NR. Management of Barrett's esophagus: A national study of practice patterns and their cost implications. Am J Gastroenterol 1999;94:3440-7.
24. van Sandick JW, Bartelsman JFWM, van Lanschot JJB, Tytgat GNJ, Obertop H. Surveillance of Barrett's oesophagus: Physicians' practices and review of current guidelines. Eur J Gastroenterol Hepatol 2000;12:111-7.
25. Smith AM, Maxwell-Armstrong CA, Welch NT, Scholefield JH. Surveillance for Barrett's oesophagus in the UK. Br J Surg 1999;276-80.
26. Sharma P, Weston A, Falk G, Johnston M, Reker D, Sampliner R. Can two upper endoscopies negative for dysplasia eliminate the need for future surveillance in patients with Barrett's esophagus? Am J Gastroenterol. 2001;96(Suppl):S36. (Abst)
27. Sampliner RE, Practice Parameters Committee of ACG. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002;97:1888-95.
28. Macdonald CE, Wicks AC, Playford RJ. Final results from 10 year cohort of patients undergoing surveillance for Barrett's Esophagus: Observational study. BMJ 2000;321:1252-5.
29. Jankowski J, Wright NA, Meltzer S, et al. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol 1999;154:965-73.
30. Splechler SJ. Disputing dysplasia. Gastroenterology 2001;120:1864-8.
31. Heitmiller RF, Redmond M, Hamilton SR. Barrett's Esophagus with high-grade dysplasia: An indication for prophylactic esophagectomy. Ann Surg 1996;224:66-71.
32. Zaninotto G, Parenti AR, Ruol A, Constantini S, Ancona E. Oesophageal resection for high-grade dysplasia in Barrett's oesophagus. Br J Surg 2000;87:1102-5.
33. Buttar N, Wang KK, Sebo TJ, et al. Extent of high-grade dysplasia in Barrett's Esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001;120:1630-9.
34. Schnell TG, Sontag SJ, Chejfec G, et al. Long-term nonsurgical management of Barrett's Esophagus with high-grade dysplasia. Gastroenterology 2001;129:1607-19.
35. Weston AP, Sharma P, Topalovski M, Richards R, Cherian R, Dixon A. Long-term follow-up of Barrett's high grade dysplasia. Am J Gastroenterol 2000;95:1888-93.
36. Levine DS, Haggitt RC, Blount PL, Rabinovitch PS, Rusch VW, Reid BJ. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's Esophagus. Gastroenterology 1993;105:40-50.
37. Reid BJ, Blount PL, Feng Z, Levine DS. Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia. Am J Gastroenterol 2000;95:3089-95.
38. Casson AG. Role of molecular biology in the follow-up of patients who have Barrett's esophagus. Chest Surg Clin N Am 2002;12:93-111.